Kiora Pharmaceuticals (KPRX) Net Income towards Common Stockholders (2014 - 2026)

Kiora Pharmaceuticals (KPRX) has 13 years of Net Income towards Common Stockholders data on file, last reported at -$2.4 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 10.26% year-over-year to -$2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.1 million (up 8.23% YoY) and the FY2025 annual result came in at -$10.8 million, down 401.42% from the prior year.
• Net Income towards Common Stockholders grew to -$2.4 million in Q1 2026, from -$6.5 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $13.5 million in Q1 2024 to a low of -$6.5 million in Q4 2025.
• A 5-year average of -$2.2 million and a median of -$2.5 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders sank 7427.78% — and 2024, when it jumped 801.62%.
• Tracing KPRX's Net Income towards Common Stockholders over 5 years: stood at -$2.5 million in 2022, then increased by 9.2% to -$2.3 million in 2023, then sank by 86.17% to -$4.2 million in 2024, then plunged by 54.29% to -$6.5 million in 2025, then surged by 62.89% to -$2.4 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$2.4 million (Q1 2026), -$6.5 million (Q4 2025), and $26806.0 (Q3 2025), per Business Quant data.